Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma

Sung Yong Kim; Seok Goo Cho; Sung Won Kim; Byung Ok Choi; Kyung Sin Park; Jihyang Lim; Chang Ki Min; Yong Goo Kim; Jong Wook Lee; Woo Sung Min

doi:10.1007/s00277-010-1114-y

Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma

Sung Yong Kim
, Seok Goo Cho
, Sung Won Kim
, Byung Ok Choi
, Kyung Sin Park
, Jihyang Lim
, Chang Ki Min
, Yong Goo Kim
, Jong Wook Lee
, Woo Sung Min

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The role of the Epstein-Barr virus (EBV) in the pathogenesis of extranodal natural killer/T-cell lymphoma (ENKTCL), and its resistance to chemotherapy raises the possibility of antiviral therapeutic strategies. The aim of this prospective pilot study was to evaluate the feasibility and effectiveness of antiviral treatment using pegylated interferon alpha-2a (pIFN α-2a) as an adjunct to induction and maintenance therapy in patients with ENKTCL. A total of seven patients with newly diagnosed EBV-positive ENKTCL were enrolled. Pegylated IFN α-2a was administered during induction chemoradiotherapy. If patients achieved a partial or complete response (PR or CR, respectively), high-dose chemotherapy with autologous stem cell transplantation (HDT/SCT) was given. After transplantation, maintenance therapy included pIFN α-2a for 3 years. Of the patients available for evaluation, all achieved a CR or PR after induction therapy but one patient relapsed before HDT/SCT. The event free survival and overall survival at 3 years were 50.0±20.4% and 66.7±19.2%, respectively. The 3-year disease-free survival after transplantation of the patients that received maintenance therapy was 80.0±17.9%. The results of this pilot study indicated that pIFN α-2a containing induction and maintenance therapy was feasible and effective for ENKTCL.

Original language	English
Pages (from-to)	693-699
Number of pages	7
Journal	Annals of Hematology
Volume	90
Issue number	6
DOIs	https://doi.org/10.1007/s00277-010-1114-y
State	Published - Jun 2011

Bibliographical note

Funding Information:
Acknowledgments This study was supported by grants from the Korea Science and Engineering Foundation (R11-2002-098-08004-0) and from the Catholic Institute of Cell Therapy Basic Science Programs Foundation during the program year 2007. The study was, in part, sponsored by Roche Pharmaceutical.

Keywords

Epstein-Barr virus
Extranodal NK/T cell lymphoma
Interferon alpha-2a

Access to Document

10.1007/s00277-010-1114-y

Cite this

Kim, S. Y., Cho, S. G., Kim, S. W., Choi, B. O., Park, K. S., Lim, J., Min, C. K., Kim, Y. G., Lee, J. W., & Min, W. S. (2011). Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma. Annals of Hematology, 90(6), 693-699. https://doi.org/10.1007/s00277-010-1114-y

@article{f7b74407a4974c1f86f1bd45bc4129fe,

title = "Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma",

abstract = "The role of the Epstein-Barr virus (EBV) in the pathogenesis of extranodal natural killer/T-cell lymphoma (ENKTCL), and its resistance to chemotherapy raises the possibility of antiviral therapeutic strategies. The aim of this prospective pilot study was to evaluate the feasibility and effectiveness of antiviral treatment using pegylated interferon alpha-2a (pIFN α-2a) as an adjunct to induction and maintenance therapy in patients with ENKTCL. A total of seven patients with newly diagnosed EBV-positive ENKTCL were enrolled. Pegylated IFN α-2a was administered during induction chemoradiotherapy. If patients achieved a partial or complete response (PR or CR, respectively), high-dose chemotherapy with autologous stem cell transplantation (HDT/SCT) was given. After transplantation, maintenance therapy included pIFN α-2a for 3 years. Of the patients available for evaluation, all achieved a CR or PR after induction therapy but one patient relapsed before HDT/SCT. The event free survival and overall survival at 3 years were 50.0±20.4\% and 66.7±19.2\%, respectively. The 3-year disease-free survival after transplantation of the patients that received maintenance therapy was 80.0±17.9\%. The results of this pilot study indicated that pIFN α-2a containing induction and maintenance therapy was feasible and effective for ENKTCL.",

keywords = "Epstein-Barr virus, Extranodal NK/T cell lymphoma, Interferon alpha-2a",

author = "Kim, \{Sung Yong\} and Cho, \{Seok Goo\} and Kim, \{Sung Won\} and Choi, \{Byung Ok\} and Park, \{Kyung Sin\} and Jihyang Lim and Min, \{Chang Ki\} and Kim, \{Yong Goo\} and Lee, \{Jong Wook\} and Min, \{Woo Sung\}",

note = "Funding Information: Acknowledgments This study was supported by grants from the Korea Science and Engineering Foundation (R11-2002-098-08004-0) and from the Catholic Institute of Cell Therapy Basic Science Programs Foundation during the program year 2007. The study was, in part, sponsored by Roche Pharmaceutical.",

year = "2011",

month = jun,

doi = "10.1007/s00277-010-1114-y",

language = "English",

volume = "90",

pages = "693--699",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

TY - JOUR

T1 - Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma

AU - Kim, Sung Yong

AU - Cho, Seok Goo

AU - Kim, Sung Won

AU - Choi, Byung Ok

AU - Park, Kyung Sin

AU - Lim, Jihyang

AU - Min, Chang Ki

AU - Kim, Yong Goo

AU - Lee, Jong Wook

AU - Min, Woo Sung

N1 - Funding Information: Acknowledgments This study was supported by grants from the Korea Science and Engineering Foundation (R11-2002-098-08004-0) and from the Catholic Institute of Cell Therapy Basic Science Programs Foundation during the program year 2007. The study was, in part, sponsored by Roche Pharmaceutical.

PY - 2011/6

Y1 - 2011/6

N2 - The role of the Epstein-Barr virus (EBV) in the pathogenesis of extranodal natural killer/T-cell lymphoma (ENKTCL), and its resistance to chemotherapy raises the possibility of antiviral therapeutic strategies. The aim of this prospective pilot study was to evaluate the feasibility and effectiveness of antiviral treatment using pegylated interferon alpha-2a (pIFN α-2a) as an adjunct to induction and maintenance therapy in patients with ENKTCL. A total of seven patients with newly diagnosed EBV-positive ENKTCL were enrolled. Pegylated IFN α-2a was administered during induction chemoradiotherapy. If patients achieved a partial or complete response (PR or CR, respectively), high-dose chemotherapy with autologous stem cell transplantation (HDT/SCT) was given. After transplantation, maintenance therapy included pIFN α-2a for 3 years. Of the patients available for evaluation, all achieved a CR or PR after induction therapy but one patient relapsed before HDT/SCT. The event free survival and overall survival at 3 years were 50.0±20.4% and 66.7±19.2%, respectively. The 3-year disease-free survival after transplantation of the patients that received maintenance therapy was 80.0±17.9%. The results of this pilot study indicated that pIFN α-2a containing induction and maintenance therapy was feasible and effective for ENKTCL.

AB - The role of the Epstein-Barr virus (EBV) in the pathogenesis of extranodal natural killer/T-cell lymphoma (ENKTCL), and its resistance to chemotherapy raises the possibility of antiviral therapeutic strategies. The aim of this prospective pilot study was to evaluate the feasibility and effectiveness of antiviral treatment using pegylated interferon alpha-2a (pIFN α-2a) as an adjunct to induction and maintenance therapy in patients with ENKTCL. A total of seven patients with newly diagnosed EBV-positive ENKTCL were enrolled. Pegylated IFN α-2a was administered during induction chemoradiotherapy. If patients achieved a partial or complete response (PR or CR, respectively), high-dose chemotherapy with autologous stem cell transplantation (HDT/SCT) was given. After transplantation, maintenance therapy included pIFN α-2a for 3 years. Of the patients available for evaluation, all achieved a CR or PR after induction therapy but one patient relapsed before HDT/SCT. The event free survival and overall survival at 3 years were 50.0±20.4% and 66.7±19.2%, respectively. The 3-year disease-free survival after transplantation of the patients that received maintenance therapy was 80.0±17.9%. The results of this pilot study indicated that pIFN α-2a containing induction and maintenance therapy was feasible and effective for ENKTCL.

KW - Epstein-Barr virus

KW - Extranodal NK/T cell lymphoma

KW - Interferon alpha-2a

UR - https://www.scopus.com/pages/publications/79956088042

U2 - 10.1007/s00277-010-1114-y

DO - 10.1007/s00277-010-1114-y

M3 - Article

C2 - 21088967

AN - SCOPUS:79956088042

SN - 0939-5555

VL - 90

SP - 693

EP - 699

JO - Annals of Hematology

JF - Annals of Hematology

IS - 6

ER -

Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this